EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Potential for Optimization of Growth Hormone Treatment in Children with Growth Hormone Deficiency, Small for Gestational Age, and Turner Syndrome in Germany: Data from the PATRO ® Children Study

Carl Joachim Partsch, Carl-Joachim Partsch, Christof Land, Roland Werner Pfäffle, Karl Otfried Schwab, Heide Sommer, German PATRO-Board

Hormone Research in Paediatrics · 2024

DOI: 10.1159/000539068 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Hormone Research in Paediatrics, 2024. Verfasst von Carl Joachim Partsch und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Endokrinologikum Hamburg, Hamburg, Germany. Hauptthemen laut MEDLINE: Turner Syndrome, Infant, Small for Gestational Age, Human Growth Hormone, Growth Disorders. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Growth hormone (GH) treatment in children with growth hormone deficiency (GHD), short children born small for gestational age (SGA), and Turner syndrome (TS) is well established. However, a variety of parameters are still under discussion to achieve optimal growth results and efficiency of GH use in real-world treatment.

Methods

German GH-treatment naïve patients of the PATRO Children database were grouped according to their start of treatment into groups of 3 years from 2007 to 2018. Time trends in age, gender, GH dose, height standard deviation score (SDS), first-year growth response, and Index of Responsiveness (IoR) were investigated in children with GHD, short children born SGA, and TS starting GH treatment in the German patient population of the PATRO Children database from 2007 to 2018 to determine specific parameters for GH treatment optimization.

Results

All patient groups started GH treatment at a relatively high chronological age (2007–2009: GHD 8.33 ± 3.19, SGA 7.32 ± 2.52, TS 8.65 ± 4.39) with a slight but not significant trend towards younger therapy start up to 2016–2018 (GHD 8.04 ± 3.36, SGA 6.67 ± 2.65, TS 7.85 ± 3.38). In the GHD and SGA groups, female patients were underrepresented compared to male patients (GHD 32.3%, SGA 43.6%) with no significant change over the 4 time periods. Patients with GHD started GH treatment at a low dose (0.026 mg/kg/day). In SGA and TS patients, GH therapy was started below the registered dose recommendation (30.0 μg/kg/day and 33.7 μg/kg/day, respectively). In the first year of treatment, the mean GH dose was increased moderately (GHD: 30.7, SGA: 35.7, TS: 40.8 μg/kg/day). There was no significant change of GH dosing over time from 2007 to 2018. The IoR was comparable between time-groups for all 3 diagnoses.

Discussion

This study shows potential for improvement of GH treatment results in GHD, SGA, and TS patients in terms of early dose adjustment and younger age at the start of treatment. This is in accordance with important parameters used in prediction models.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Turner SyndromeInfant, Small for Gestational AgeHuman Growth HormoneGrowth DisordersHumansFemaleMaleGermanyChildChild, PreschoolInfant, NewbornBody HeightAdolescentInfant

Stichwörter der Autor:innen

Growth hormone deficiencyGrowth hormone treatmentPATROShort for gestational ageTurner syndrome

Substanzen

Human Growth Hormone

Autor:innen und Institutionen

  • Department of Pediatrics, Endokrinologikum Hamburg, Hamburg, Germany.
  • Zentrum für Kinder- und Jugendendokrinologie, Gauting, Germany.
  • Department of Pediatric Endocrinology, University Hospital Leipzig, Leipzig, Germany.
  • Department of Pediatrics, University Hospital Freiburg, Freiburg, Germany.
  • Sandoz Germany c/o Hexal AG, Holzkirchen, Germany.

Zitieren

APA

Partsch, C. J., Partsch, C. J., Land, C., Pfäffle, R. W., Schwab, K. O., Sommer, H., & German PATRO-Board (2024). Potential for Optimization of Growth Hormone Treatment in Children with Growth Hormone Deficiency, Small for Gestational Age, and Turner Syndrome in Germany: Data from the PATRO ® Children Study. Hormone Research in Paediatrics. https://doi.org/10.1159/000539068

Vancouver

Partsch CJ, Partsch CJ, Land C, Pfäffle RW, Schwab KO, Sommer H, et al. Potential for Optimization of Growth Hormone Treatment in Children with Growth Hormone Deficiency, Small for Gestational Age, and Turner Syndrome in Germany: Data from the PATRO ® Children Study. Hormone Research in Paediatrics. 2024. doi:10.1159/000539068

BibTeX
@article{Partsch2024,
  author = {Partsch, Carl Joachim and Partsch, Carl-Joachim and Land, Christof and Pfäffle, Roland Werner and Schwab, Karl Otfried and Sommer, Heide and German PATRO-Board, German PATRO-Board},
  title = {Potential for Optimization of Growth Hormone Treatment in Children with Growth Hormone Deficiency, Small for Gestational Age, and Turner Syndrome in Germany: Data from the PATRO ® Children Study},
  journal = {Hormone Research in Paediatrics},
  year = {2024},
  doi = {10.1159/000539068}
}
Kostenlos starten →